Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT06591351

Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA

Led by Kafrelsheikh University · Updated on 2024-09-19

870

Participants Needed

1

Research Sites

127 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Along with the current clinical trial, the efficacy and safety of a 300 mg loading dose of clopidogrel and 300 mg loading aspirin administered within 24 hours of the first-ever large-vessel minor stroke or TIA compared to 200 mg cilostazol and 300 mg loading aspirin were assessed through NIHSS, mRS, and possible adverse effects

CONDITIONS

Official Title

Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 75 years
  • First-ever large-vessel minor ischemic stroke or transient ischemic attack (TIA)
  • Received antiplatelet treatment within 24 hours of ischemic stroke onset
  • Not eligible for rt-PA treatment
Not Eligible

You will not qualify if you...

  • Not followed up for 90 days after enrollment
  • NIHSS score less than 5 or rapidly resolving symptoms before imaging
  • History of persistent or recurrent central nervous system disorders (e.g., epilepsy, meningioma, multiple sclerosis, head trauma with residual deficit)
  • Clinical seizures at stroke onset
  • Symptoms of major organ failure or active malignancies
  • Acute myocardial infarction within the past six weeks
  • Use of warfarin or regular ticagrelor within the week before admission
  • Chemotherapy within the past year
  • Active peptic ulcers, gastrointestinal surgery, or bleeding history within the last year
  • Major surgery within the last three months
  • Known allergy to study drugs
  • INR greater than 1.4 or PT greater than 18
  • Blood glucose less than 50 or greater than 400 mg/dL
  • Blood pressure less than 90/60 or greater than 185/110 mmHg on admission
  • Platelet count less than 100,000
  • Pregnancy or lactation
  • Stroke due to venous thrombosis or following cardiac arrest or severe hypotension
  • Contraindications to study drugs

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Kafr Elsheikh University Hospital

Kafr ash Shaykh, Egypt, 33511

Actively Recruiting

Loading map...

Research Team

M

mohamed G. Zeinhom, MD

CONTACT

S

sherihan R. ahmed, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here